Funding for this research was provided by:
Horizon 2020 (731560)
Article History
Received: 15 October 2020
Accepted: 24 February 2021
First Online: 4 April 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: RH reports having received speaker honoraria from Eli Lilly and Novo Nordisk, serving on advisory panels for Eli Lilly and Novo Nordisk; receiving license fees from BBraun and Medtronic; having served as a consultant to BBraun, patents and patent applications related to closed-loop insulin delivery, and director at CamDiab. BK, JL, CB and DR have no competing interests to report.